Christine A. Nash

Christine is a marketing and commercial executive with 20 years of experience in emerging biopharmaceutical companies. As Principal at Chatiemac Consulting, LLC, she provides strategic and commercial planning guidance to biotechnology companies developing medications for rare diseases. Christine also currently serves as Board Chair and senior advisor to the President and CEO at The CM Group, an integrated healthcare agency focused on providing scientific and commercialization strategies and services to life sciences companies. Previously, Christine was at Hyperion Therapeutics, Inc., where she held roles of increasing responsibility in marketing and business development, including Chief Commercial Officer, until Hyperion’s acquisition by Horizon Pharma. Prior to Hyperion, Christine held marketing roles at Cotherix, Inc., until its acquisition by Actelion. Early in her career, she was a Product Manager at Genesoft Pharmaceuticals until its acquisition by Oscient Pharmaceuticals.

Christine earned both a B.A. with honors in public policy and an M.B.A. from Stanford University.